Copper-Based Complexes with Adamantane Ring-Conjugated bis (3,5-Dimethyl-pyrazol-1-yl)acetate Ligand as Promising Agents for the Treatment of Glioblastoma.
Maria Beatrice MorelliMiriam CavigliaCarlo SantiniJo' Del GobboLaura ZeppaFabio Del BelloGianfabio GiorgioniAlessandro PiergentiliWilma QuagliaChiara BattocchioFederica BertelàSimone AmatoriCarlo MeneghiniGiovanna IucciAndrea BearzottiAlessandro DolmellaMichele Di PalmaMaura PelleiPublished in: Journal of medicinal chemistry (2024)
The new ligand L 2Ad , obtained by conjugating the bifunctional species bis(3,5-dimethylpyrazol-1-yl)-acetate and the drug amantadine, was used as a chelator for the synthesis of new Cu complexes 1 - 5 . Their structures were investigated by synchrotron radiation-induced X-ray photoelectron spectroscopy (SR-XPS), near-edge X-ray absorption fine structure (NEXAFS) spectroscopy, and by combining X-ray absorption fine structure (XAFS) spectroscopy techniques and DFT modeling. The structure of complex 3 was determined by single-crystal X-ray diffraction analysis. Tested on U87, T98, and U251 glioma cells, Cu(II) complex 3 and Cu(I) complex 5 decreased cell viability with IC 50 values significantly lower than cisplatin, affecting cell growth, proliferation, and death. Their effects were prevented by treatment with the Cu chelator tetrathiomolybdate, suggesting the involvement of copper in their cytotoxic activity. Both complexes were able to increase ROS production, leading to DNA damage and death. Interestingly, nontoxic doses of 3 or 5 enhanced the chemosensitivity to Temozolomide.
Keyphrases
- high resolution
- dna damage
- radiation induced
- dual energy
- single molecule
- electron microscopy
- metal organic framework
- air pollution
- aqueous solution
- solid state
- mass spectrometry
- oxidative stress
- ionic liquid
- radiation therapy
- photodynamic therapy
- emergency department
- computed tomography
- dna repair
- density functional theory
- combination therapy
- newly diagnosed
- atomic force microscopy
- anti inflammatory
- adverse drug
- contrast enhanced
- oxide nanoparticles